Nick Powell

Has grant

Reader in Gastroenterology

Imperial College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Nick Powell is a Reader in Gastroenterology at Imperial College London, UK. His research focuses on the gut microbiota's role in vaccination responses, as well as treatment strategies in inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Recent publications include studies on therapeutic approaches, disease pathogenesis, and predictive models for disease progression.

Recent Grants

Grant: Close

The role of miR142 in mucosal immunity

Open Date: 2018-09-17

Close Date: 2019-09-17

Grant: Close

MICA: Targeted Regulatory T Cell Therapy for Inflammatory Bowel Disease

Open Date: 2016-08-14

Close Date: 2023-10-13

Grant: Close

Exploring host-gut microbial genetic and immune interactions using twins

Open Date: 2016-03-31

Close Date: 2019-09-29

Grant: Close

The role of microRNA-142 in mucosal immunity

Open Date: 2014-09-01

Close Date: 2019-09-17

Grant: Close

Functional dyspepsia: Characterisation of the immunopathology and testing a novel therapeutic strategy.

Open Date: 2014-01-01

Close Date: 2019-12-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (23)

Natalie Prescott

King’s College London

UNITED KINGDOM

Nick Powell

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Patient-Specific Regulatory Network Rewiring in Inflammatory Bowel Disease: How Genetic Polymorphisms Divert Incoming Signals and Contribute to Disease Pathogenesis

ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment Response

The emerging role of the gut microbiota in vaccination responses

Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota research

Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn’s Disease: A Three-Patient Case Series

Deciphering the microbiome–metabolome landscape of an inflammatory bowel disease inception cohort

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Plasma interleukin-22 concentration and disease activity in inflammatory bowel disease

Widening access to recombinant zoster vaccination in IBD

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

A population of naive-like CD4+ T cells stably polarized to the TH1 lineage

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

Cytokine responsive networks in human colonic epithelial organoids unveil a molecular classification of inflammatory bowel disease

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.

Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity.

Collaborators (23)

Natalie Prescott

Christian Selinger

Nicholas Kennedy

Richard Alexander Speight

Stephen Henderson

Sophie Papa

Stephen Hanauer

Jane Howard

James L Alexander

J. R. Fraser Cummings

Tamas Korcsmaros

Naomi McGregor

Alessandro Armuzzi

Shaji Sebastian

Arno R. Bourgonje

Robert Perry

Craig Mowat

Polychronis Pavlidis

Gavin Bewick

Jonathan Macdonald

Mansoor Saqi

Christopher A. Lamb

Emma Houlder

Make your next move.